Justice Michael Hyman told Chicago why a dead woman's shortened life was worth $30 million on top of her death, and Johnson & Johnson says it will ask the Illinois Supreme Court to take the ruling back.
On July 10, 2026, Justice Michael Hyman told Chicago why a dead woman's shortened life was worth $30 million on top of her death. He wrote it into 2026 IL App (1st) 242199, the ruling in which the Illinois Appellate Court, First District upheld a Cook County jury's $45 million verdict against Johnson & Johnson and Kenvue. "The Survival Act damages compensate Garcia for the loss of years of life, an injury she sustained once she learned that mesothelioma would have a drastic and permanent effect," Hyman wrote for the majority. Thirty million of that $45 million belongs to one sentence, a damages category no Illinois court had blessed before. Johnson & Johnson said it will ask the state's highest court to take it back.
That is the posture shift. Even the dissent notes that neither the panel nor the parties knew of any prior Illinois case awarding shortened-life-expectancy damages this way. Hyman's opinion holds the two injuries apart: the Survival Act compensates what Garcia suffered before death, the Wrongful Death Act compensates what her family lost after it. Johnson & Johnson called that stacking and double recovery. The majority rejected the label, writing that double recovery means the same injury compensated twice, and these were different injuries suffered by different claimants. A Cook County jury priced both, and an appellate panel signed off on the math.
The record mechanism is the Survival Act itself, paired with the jury's own verdict form. Theresa Garcia was diagnosed with mesothelioma in January 2020, at 52, after asbestos exposure her lawyers traced to Johnson & Johnson's talc baby powder. She filed suit, then died in July 2020, before trial. Stephanie Salcedo took over the case as administrator of Garcia's estate. The jury's verdict split the money three ways: $12 million to Salcedo and her siblings on the wrongful death claim, $3 million for Garcia's pain, suffering, loss of normal life, and disfigurement on the survival claim, and $30 million for the years Garcia would have lived had the disease not cut her life short. The trial court later added $2,657,835.92 in prejudgment interest. Geologist Mark Bailey testified that talc Johnson & Johnson sourced from mines in Italy and Vermont contained asbestos fibers. Pulmonologist Steven Haber testified that the exposure was a substantial factor in causing her mesothelioma. The jury credited both, and Hyman's opinion held the verdict together on appeal.
Justice Celia Gamrath did not sign that part of it. In her partial dissent, she wrote that the majority's ruling "will now turn shortened life expectancy damages into a routine component of every survival action paired with a wrongful death claim." She is naming the mechanism, not just the dollar figure. Once one Illinois appellate panel accepts a lost-years category as its own compensable harm, any estate with a survival claim and a wrongful death claim can ask a jury to price both. Johnson & Johnson's worldwide vice president of litigation, Erik Haas, said the company will appeal, adding the company remains "confident that further review will confirm that the law does not permit the unprecedented recovery allowed here."
Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.
The tactical map runs through where this case sits. Cook County is a venue the American Tort Reform Association, a defense-side advocacy group, has repeatedly flagged in its Judicial Hellholes report, and this ruling gives plaintiffs' counsel a new category to plead there before any other Illinois court has weighed in against it. The mechanism Gamrath is pointing at is procedural, not moral. In her accounting, the jury awarded $30 million for 30 years of life Garcia never lived, on top of the $12 million her family collected for the death itself, a layering she wrote "risks double recovery" and "borders on hedonic damages." Her bottom line names the forum: if Illinois is to adopt this sweeping expansion of survival recovery, she wrote, it should come from the supreme court or the General Assembly. For any defendant with a mass-tort docket in Cook County, that is the exposure line to watch, not the $30 million itself.
The next fight is procedural before it is substantive. Johnson & Johnson's path runs through a petition for leave to appeal to the Illinois Supreme Court, the only forum that can undo a published First District ruling statewide. No filing date is on the record yet. Until that petition is filed and either accepted or denied, 2026 IL App (1st) 242199 stands as controlling authority in the First District, and any trial judge in Cook County can let a plaintiff's counsel ask a jury for a reduced-lifespan line item under it.
Justice Celia Gamrath's dissent warned the ruling will now turn shortened life expectancy damages into a routine component of every survival action paired with a wrongful death claim.
For now, the $45 million verdict holds, and so does the $30 million inside it. Hyman's sentence survived Gamrath's dissent and survived the panel. What did not survive was J&J's argument that the category was never available, and the company has already said it will not let that stand. The next docket entry to watch is not another verdict. It is the petition Johnson & Johnson has promised to file, asking seven justices in Springfield to decide whether Cook County juries keep pricing the years a plaintiff never lived to see.
The Executive Briefing is six questions. It shows you exactly where the gaps are.
Take the Executive Briefing →Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.